Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 162 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective June 28, 2022 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 How you can do your part in the AI transformation of... October 7, 2025 Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... September 4, 2024 Load more HOT NEWS Breast Cancer Patient Credits Persistent Commercial Messaging for Saving Her Life Working Mom with Stage II Breast Cancer Receives Custom Wig Made... Why it’s difficult to estimate the number of extra cancer deaths... EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab
